
发表一篇学和医学成像类SCI论文
需要多少钱?
Abstract:
BACKGROUND:The American Joint Committee on Cancer (AJCC) maintains that the eighth edition of its Staging Manual (AJCC8) has improved accuracy compared to the seventh (AJCC7). However, there are concerns that implementation may disrupt analysis of active clinical trials for stage III patients. We used an independent cohort of melanoma patients to test the extent to which AJCC8 has improved prognostic accuracy compared to AJCC7. METHODS:We analyzed a cohort of 1,315 prospectively enrolled patients. We assessed primary tumor and nodal classification of stage I-III patients using AJCC7 and AJCC8 to assign disease stages at diagnosis. We compared recurrence-free (RFS) and overall survival (OS) using Kaplan-Meier curves and log-rank tests. We then compared concordance indices of discriminatory prognostic ability and area under the curve (AUC) of 5-year survival to predict RFS/OS. All statistical tests were two-sided. RESULTS:Stage IIC continued to have worse outcomes than those for stage IIIA patients, with 5-year RFS of 26.5% (95%CI=12.8-55.1%) vs. 56.0% (95%CI=37.0-84.7%) by AJCC8 (P = 0.002). For stage I, removing mitotic index as T classification factor decreased its prognostic value, although not statistically significantly (RFS C-index=0.63 [95%CI=0.56-0.69] to 0.56 [95%CI=0.49-0.63], P = 0.07; OS C-index=0.48 [95%CI=0.38-0.58] to 0.48 [95%CI=0.41-0.56], P = 0.90). For stage II, prognostication remained constant (RFS C-index=0.65 [95%CI=0.57-0.72]; OS C-index=0.61 [95%CI=0.50-0.72]), and. For stage III, AJCC8 yielded statistically significantly enhanced prognostication for RFS (C-index=0.65 [95%CI=0.60-0.70] to 0.70 [95%CI=0.66-0.75], P = 0.01). CONCLUSIONS:Compared with AJCC7, we demonstrate that AJCC8 enables more accurate prognosis for patients with stage III melanoma. Restaging a large cohort of patients can enhance the analysis of active clinical trials.
展开更多
最新影响因子:11.816 | 期刊ISSN:0027-8874 | CiteScore: |
出版周期: | 是否OA:YES | 出版年份:0 |
自引率:1.60% | 研究方向:ONCOLOGY- |
出版地区:UNITED STATES |
SCI期刊coverage:Science Citation Index Expanded(科学引文索引扩展)
专业编辑在线一对一答疑及时解决您的问题
Publishing the best original research papers in oncology from around the world and internationally acclaimed as the source for the most up-to-date information, the Journal of the National Cancer Institute is now available by subscription from Oxford University Press. Each issue is also packed with extensive news about important cancer-related science, policy, politics, and people. In addition, there are editorials and reviews by experts in the field, book reviews, and commentaries on timely topics. The Journal of the National Cancer Institute publishes manuscripts that describe new findings of particular significance in any area relating to cancer, as well as associated news items, reviews, and opinion pieces. The Journal employs a process of rigorous yet rapid review of submitted manuscripts so that findings of high scientific and medical interest can be published with minimum delay.
《国家癌症研究所学报》是牛津大学出版社出版的最新信息来源之一,发表了世界各地和国际上最优秀的肿瘤学原始研究论文。每一期都充斥着与癌症有关的重要科学、政策、政治和人民的广泛新闻。此外,还有该领域专家的社论和评论、书评和适时主题评论。《国家癌症研究所杂志》出版的手稿描述了与癌症有关的任何领域的特别重要的新发现,以及相关的新闻项目、评论和评论文章。该杂志采用了一个严格而快速的审查提交的手稿的过程,以便高科学和医学利益的调查结果可以在最短的时间内出版。
大类(学科) | 小类(学科) | 学科排名 |
医学 |
ONCOLOGY (肿瘤学) 1区 |
10/223 |
年度总发文量 | 年度论文发表量 | 年度综述发表量 |
133 | 111 | 22 |
引文计数(2018)
文献(2015-2017)
次引用
篇文献
序号 | 类别 | 排名 | 百分位 |
推荐刊物均可到国家新闻出
版总署网站查询正刊
可签署保密协议 ,不透露任
何用户信息可跟踪进程,全程
协议
1对1服务,7x24小时在线
14年经验沉淀,实体公司
运营
liting7111
审稿时间: 2个月内 接受率: 比较困难(25%命中)
影响因子:2.995
ISSN:0028-3940
研究方向:医学-核医学
影响因子:2.324
ISSN:1051-2284
研究方向:医学-核医学
影响因子:3.156
ISSN:1869-1439
研究方向:CLINICAL NEUROLOGY-RADIOLOGY, NUCLEAR MEDICINE & M
影响因子:4.6
ISSN:0150-9861
研究方向:医学-核医学
影响因子:1.764
ISSN:1591-0199
研究方向:CLINICAL NEUROLOGY-RADIOLOGY, NUCLEAR MEDICINE & M
影响因子:4.966
ISSN:0195-6108
研究方向:医学-核医学
影响因子:3.005
ISSN:0301-0449
研究方向:医学-核医学
影响因子:2.396
ISSN:1793-5458
研究方向:OPTICS-RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGI
影响因子:3.632
ISSN:1084-9785
研究方向:医学-核医学
JNCI-Journal of the National Cancer Institute 投稿经验
(由下方点评分析获得,1人参与,8199人阅读)